| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$54.4M | ROE | −43.12% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $186.6M | Trading Days | 1249 |
| 52W High | 10.08 |
| 52W Low | 2.90 |
| % Off High | −57.94% |
| YTD | −35.56% | 1Y | 8.44% |
| 3Y | −58.14% | Since incept. (ann.) | −24.31% |
| Ann. Volatility (1Y) | 103.76% | Ann. Volatility (3Y) | 116.96% |
| Sharpe (1Y) | 0.62 | Sharpe (3Y) | 0.36 |
| Max Drawdown (1Y) | −57.56% | Max Drawdown (3Y) | −90.36% |
| Beta (3Y, vs SPY) | 2.65 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
| VERU | VERU INC. | $189.5M | — |
| WHWK | Whitehawk Therapeutics, Inc. | $182.0M | — |
| INDP | Indaptus Therapeutics, Inc. | $195.9M | — |
| CAMP | Camp4 Therapeutics Corp | $177.6M | — |
| RNA | Atrium Therapeutics, Inc. | $196.5M | — |
| GLSI | Greenwich LifeSciences, Inc. | $197.4M | — |
| NERV | Minerva Neurosciences, Inc. | $199.4M | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $170.7M | 2.8 |
| ANTX | AN2 Therapeutics, Inc. | $169.3M | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. |
| $168.3M |
| — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $164.7M | — |
